Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Adv Exp Med Biol. 2020;1177:269-295. doi: 10.1007/978-981-15-2517-9_7.
Heart failure (HF) is defined as a clinical syndrome resulting from structural or functional impairment of ventricular fillings or ejections of blood. Currently, HF is divided into three groups which include HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with midrange EF (HFmrEF). Even though major advances have been made in treating HFrEF during the past decades, heart failure is a fatal disease. In this review, we briefly summarize the current advances in pharmaceutical managements for heart failure, which includes drugs used in acute heart failure as well as those that prevent heart failure progression, in each category major clinical trials are also described. In addition, information about some of potential new drugs are also mentioned. Traditional Chinese medicine also shows its potential in treating HF, and we are still lack of medicine to treat HFpEF.
心力衰竭（HF）被定义为一种由心室充盈或血液射血的结构或功能障碍引起的临床综合征。目前，HF 分为三组，包括射血分数降低的心力衰竭（HFrEF）、射血分数保留的心力衰竭（HFpEF）和射血分数中间范围的心力衰竭（HFmrEF）。尽管在过去几十年中，HFrEF 的治疗取得了重大进展，但心力衰竭仍然是一种致命的疾病。在这篇综述中，我们简要总结了心力衰竭药物治疗的最新进展，包括急性心力衰竭中使用的药物以及预防心力衰竭进展的药物，每个类别中还描述了主要的临床试验。此外，还提到了一些潜在新药的信息。中药在治疗心力衰竭方面也显示出其潜力，而我们仍然缺乏治疗 HFpEF 的药物。
